Galmed Pharmaceuticals Ltd.
GLMD
$1.56
$0.00430.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 52.76% | -17.75% | -44.47% | -35.22% | -35.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.59% | -9.78% | -23.57% | -34.69% | -34.69% |
| Operating Income | -72.59% | 9.78% | 23.57% | 34.69% | 34.69% |
| Income Before Tax | -122.97% | 13.41% | -59.18% | 29.76% | 29.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -122.97% | 13.41% | -59.18% | 29.76% | 29.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.97% | 13.41% | -59.18% | 29.76% | 29.76% |
| EBIT | -72.59% | 9.78% | 23.57% | 34.69% | 34.69% |
| EBITDA | -81.91% | 10.68% | 23.36% | 38.35% | 38.35% |
| EPS Basic | 61.72% | 70.40% | 88.19% | 81.25% | 85.49% |
| Normalized Basic EPS | 69.79% | 70.40% | 91.23% | 81.25% | 85.49% |
| EPS Diluted | 61.72% | 70.40% | 88.19% | 81.25% | 85.49% |
| Normalized Diluted EPS | 69.79% | 70.40% | 91.23% | 81.25% | 85.49% |
| Average Basic Shares Outstanding | 482.42% | 192.52% | 1,248.15% | 274.71% | 384.21% |
| Average Diluted Shares Outstanding | 482.42% | 192.52% | 1,248.15% | 274.71% | 384.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |